Trial Profile

A Phase 1 Study of LY2875358 in Patients With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emibetuzumab (Primary) ; Erlotinib; Trametinib
Indications Bone metastases; Cancer; Colon cancer; Gastrointestinal cancer; Liver cancer; Liver metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man
Sponsors Eli Lilly and Company

Most Recent Events

14 Feb 2017 Status changed from active, no longer recruiting to completed.
25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 31 Mar 2017.
10 Oct 2016 Results (n=37) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com